Trilaciclib to protect bone marrow after head and neck cancer surgery and chemoradiation
Part of Cancer clinical trials.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer (mouth, throat, voice box) that needed surgery and now requires chemo and radiation.
- Your cancer was stage T1-4N0-3M0 and you had all of it removed with surgery.
- Your surgery report shows at least one high-risk factor, like a positive margin or cancer in lymph nodes.
- You are in good general health (able to do daily activities) and your blood counts and organ function are normal.
- You have not had previous chemotherapy or radiation to the head and neck area, and you don't have HIV, active hepatitis, or other serious illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests a combination of two drugs, trilaciclib and immunotherapy, for people with head and neck squamous cell carcinoma that has spread or come back and can't be treated with surgery or radiation. The goal is to see if this combination helps control the cancer.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This study tests a new drug called trilaciclib, which is added to standard chemotherapy given before breast cancer surgery. The goal is to see if it helps shrink the tumor and possibly reduces side effects like low blood cell counts, making the treatment easier to tolerate.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.